Education
About Us
Working with TipRanks
Follow Us
Zai Lab (ZLAB)
NASDAQ:ZLAB
ZLAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.48 - $39.77
Previous CloseN/A
Volume273.50K
Average Volume (3M)1.19M
Market Cap
$4.01B
Enterprise Value$1.78B
Total Cash (Recent Filing)-$13.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 13, 2025EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding109,628,370
10 Day Avg. Volume907,578
30 Day Avg. Volume1,188,027
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.51
Price to Cash Flow (P/CF)-17.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.09
Enterprise Value/Ebitda-7.32
Forecast
1Y Price Target
$54.03Price Target Upside48.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Future Growth PotentialManagement provided an optimistic revenue guidance for 2025, expecting a 40.4%-47.9% year-over-year increase, indicating strong growth potential.
Product SalesVYVGART showed an impressive sales ramp-up, significantly contributing to the company's overall revenue growth.
Revenue GrowthZai Lab registered a significant increase in total revenue by 49.6%, aligning with the forecast and driven by the ramp-up of VYVGART.
Bears Say
CompetitionRising competition for its core product is expected to offset the benefits of new product launches.
Core Product PerformanceSome core products like Zejula and Optune have seen soft performance, impacting overall growth.
Stock Price LimitationRecent positive news and product approvals have already been factored into the stock price, limiting short-term upside potential.
---
Ownership Overview
1.31% Insiders
20.21% Mutual Funds
21.69% Other Institutional Investors
55.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZLAB FAQ
What was Zai Lab’s price range in the past 12 months?
Zai Lab lowest stock price was $13.48 and its highest was $39.77 in the past 12 months.
What is Zai Lab’s market cap?
Zai Lab’s market cap is $4.01B.
When is Zai Lab’s upcoming earnings report date?
Zai Lab’s upcoming earnings report date is May 13, 2025 which is in 40 days.
How were Zai Lab’s earnings last quarter?
Zai Lab released its earnings results on Feb 27, 2025. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.651 by -$0.149.
Is Zai Lab overvalued?
According to Wall Street analysts Zai Lab’s price is currently Undervalued.
Does Zai Lab pay dividends?
Zai Lab does not currently pay dividends.
What is Zai Lab’s EPS estimate?
Zai Lab’s EPS estimate is -0.46.
How many shares outstanding does Zai Lab have?
Zai Lab has 109,628,370 shares outstanding.
What happened to Zai Lab’s price movement after its last earnings report?
Zai Lab reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.651. Following the earnings report the stock price went down -1.967%.
Which hedge fund is a major shareholder of Zai Lab?
Currently, no hedge funds are holding shares in ZLAB
---
Zai Lab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.03 (48.31% Upside)
$54.03 (48.31% Upside)
Blogger Sentiment
Bullish
ZLAB Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 503.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $214.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
123.02%
12-Months-Change
Fundamentals
Return on Equity
-31.41%
Trailing 12-Months
Asset Growth
14.42%
Trailing 12-Months
Company Description
Zai Lab
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
---
ZLAB Company Deck
---
ZLAB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong revenue growth, successful product launches, and pipeline advancements. Despite some challenges, such as limited immediate impact from certain product launches and competitive pressures, the company is on track towards profitability and maintains a strong cash position.Read More>---
ZLAB Stock 12 Month Forecast
Average Price Target
$54.03
▲(48.31% Upside)
Technical Analysis
Option Care Health
―
PTC Therapeutics
―
Elanco Animal Health
―
Avidity Biosciences
―
Sotera Health
―
Best Analysts Covering ZLAB
1 Year
1 Year Success Rate
9/13 ratings generated profit
1 Year Average Return
+25.24%
reiterated a buy rating 23 days ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +25.24% per trade.
---